EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combining SiRPα decoy–coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells

Evangelos Stefanidis, Aikaterini Semilietof, Julien Pujol, Bili Seijo, Kirsten Scholten, Vincent Zoete, Olivier Michielin, Raphael Sandaltzopoulos, George Coukos, Melita Irving

Journal of Clinical Investigation · 03.06.2024 · 134 (11)

DOI: 10.1172/jci161660 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 23.04.2024. Verfasst von Evangelos Stefanidis und 9 weiteren Autor:innen. Beteiligte Einrichtung: Ludwig Institute for Cancer Research, Department of Oncology, University of Lausanne (UNIL) and University Hospital of Lausanne (CHUV), Lausanne, Swi…. Hauptthemen laut MEDLINE: Macrophages, Phagocytosis, Receptors, Immunologic. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Science Foundation, Ludwig Institute for Cancer Reasearch, Fondation ISREC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The adoptive transfer of T cell receptor–engineered (TCR-engineered) T cells (ACT) targeting the HLA-A2–restricted cancer-testis epitope NY-ESO-1 157–165 (A2/NY) has yielded favorable clinical responses against several cancers. Two approaches to improve ACT are TCR affinity optimization and T cell coengineering to express immunomodulatory molecules that can exploit endogenous immunity. By computational design we previously developed a panel of binding-enhanced A2/NY-TCRs including A97L, which augmented the in vitro function of gene-modified T cells as compared with WT. Here, we demonstrated higher persistence and improved tumor control by A97L–T cells. In order to harness macrophages in tumors, we further coengineered A97L–T cells to secrete a high-affinity signal regulatory protein α (SiRPα) decoy (CV1) that blocks CD47. While CV1-Fc–coengineered A97L–T cells mediated significantly better control of tumor outgrowth and survival in Winn assays, in subcutaneous xenograft models the T cells, coated by CV1-Fc, were depleted. Importantly, there was no phagocytosis of CV1 monomer–coengineered T cells by human macrophages. Moreover, avelumab and cetuximab enhanced macrophage-mediated phagocytosis of tumor cells in vitro in the presence of CV1 and improved tumor control upon coadministration with A97L–T cells. Taken together, our study indicates important clinical promise for harnessing macrophages by combining CV1-coengineered TCR–T cells with targeted antibodies to direct phagocytosis against tumor cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MacrophagesPhagocytosisReceptors, ImmunologicAnimalsHumansMiceAntigens, DifferentiationAntigens, NeoplasmCD47 AntigenCell Line, TumorHLA-A2 AntigenImmunotherapy, AdoptiveReceptors, Antigen, T-CellT-LymphocytesXenograft Model Antitumor AssaysMaleFemale

Stichwörter der Autor:innen

Cancer immunotherapyImmunologyInnate immunityT cellsTherapeutics

Substanzen

Antigens, DifferentiationAntigens, NeoplasmCD47 AntigenCD47 protein, humanHLA-A2 AntigenReceptors, Antigen, T-CellReceptors, ImmunologicSIRPA protein, human

Autor:innen und Institutionen

  • Ludwig Institute for Cancer Research, Department of Oncology, University of Lausanne (UNIL) and University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
  • Department of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Greece.
  • Swiss Institute of Bioinformatics, Lausanne, Switzerland.
  • Precision Oncology, University Hospital of Geneva (HUG), Geneva, Switzerland.

Förderung

  • Swiss National Science Foundation
  • Ludwig Institute for Cancer Reasearch
  • Fondation ISREC
  • Prostate Cancer Foundation
  • Carigest Foundation
  • already noted below

Zitieren

APA

Stefanidis, E., Semilietof, A., Pujol, J., Seijo, B., Scholten, K., Zoete, V., Michielin, O., Sandaltzopoulos, R., Coukos, G., & Irving, M. (2024). Combining SiRPα decoy–coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells. Journal of Clinical Investigation, 134(11). https://doi.org/10.1172/jci161660

Vancouver

Stefanidis E, Semilietof A, Pujol J, Seijo B, Scholten K, Zoete V, et al. Combining SiRPα decoy–coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells. Journal of Clinical Investigation. 2024;134(11). doi:10.1172/jci161660

BibTeX
@article{Stefanidis2024,
  author = {Stefanidis, Evangelos and Semilietof, Aikaterini and Pujol, Julien and Seijo, Bili and Scholten, Kirsten and Zoete, Vincent and Michielin, Olivier and Sandaltzopoulos, Raphael and Coukos, George and Irving, Melita},
  title = {Combining SiRPα decoy–coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  volume = {134},
  number = {11},
  doi = {10.1172/jci161660}
}
Kostenlos starten →